Retatrutide side effects reported in Phase 3 clinical trials most commonly include nausea, vomiting, diarrhea, and constipation. These gastrointestinal effects are similar to other GLP-1 class drugs. Because retatrutide is still investigational, the full safety profile is not yet complete.
Direct answer: The most common retatrutide side effects are gastrointestinal: nausea (reported in approximately 40-50% of trial participants), diarrhea (30-40%), vomiting (20-30%), and constipation (15-25%). Most side effects occur during the dose escalation phase and decrease over time. Less common side effects include increased heart rate, fatigue, and injection site reactions. Serious side effects are rare but being monitored. Retatrutide is not FDA approved, and all safety data is preliminary from ongoing trials.
If you are researching retatrutide, understanding potential retatrutide side effects is essential before considering any telehealth intake or clinical trial participation. Unlike over-the-counter supplements that rarely disclose adverse event data, retatrutide is being studied under strict FDA oversight. The official manufacturer Eli Lilly publishes trial results on clinicaltrials.gov. This page summarizes known retatrutide side effects from published Phase 2 data and preliminary Phase 3 reports, with outbound links to NIH and PubMed sources.
The most common retatrutide side effects are gastrointestinal. Nausea affects nearly half of participants during the first few weeks. Vomiting occurs less frequently but is significant enough that trials include dose titration protocols to reduce severity. Diarrhea and constipation are both reported, with diarrhea slightly more common. These effects are directly related to GLP-1 agonism, which slows gastric emptying. The triple receptor mechanism (adding glucagon) may increase energy expenditure but also potentially increases nausea risk compared to dual agonists.
Compared to standard GLP-1 drugs like semaglutide, retatrutide side effects appear similar in type but may have slightly higher rates of nausea during the initial escalation phase. According to research published on PubMed, triple agonists show dose-dependent GI effects. Most participants who continue past 8 weeks report significant reduction in symptom severity.
Where many generic weight loss supplements claim "no side effects," retatrutide is a potent investigational drug with predictable, manageable side effects. A clinician should monitor your response, especially during the first month.
Less common retatrutide side effects include increased heart rate (an average increase of 1-3 beats per minute observed in some trials), fatigue, headache, and injection site reactions (redness, itching, swelling). Pancreatitis is a known risk for GLP-1 agonists, though rare. Trial protocols specifically monitor for pancreatitis symptoms including severe abdominal pain. Gallbladder disease (gallstones) has been reported with other GLP-1 drugs and is being tracked in retatrutide trials.
A specific concern for retatrutide is the glucagon pathway's effect on heart rate and blood pressure. Glucagon can increase heart rate as part of its energy-expending mechanism. Early data suggests the increase is small and not clinically significant for most people, but longer-term data is needed. Anyone with existing heart conditions should have a thorough cardiac evaluation before considering retatrutide.
Serious warning: Retatrutide is contraindicated for people with a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2. Thyroid C-cell tumors have been observed in animal studies with GLP-1 agonists. Do not use retatrutide if you have these conditions.
Retatrutide side effect risks are higher for certain groups. People with a history of severe gastrointestinal disease (gastroparesis, inflammatory bowel disease, severe reflux) may not tolerate the GI effects. Those with a history of pancreatitis should avoid GLP-1 class drugs unless specifically cleared by a specialist. Pregnant or breastfeeding women should not use retatrutide. Anyone with diabetic retinopathy should have an eye exam before starting, as rapid blood sugar changes can worsen retinopathy.
Unlike herbal supplements that claim universal safety, retatrutide is a prescription-strength investigational drug. A licensed clinician must evaluate your medical history, current medications (especially insulin or sulfonylureas which can cause hypoglycemia), and organ function before any use. The telehealth intake link on this site connects you to a clinician who performs this evaluation.
Managing retatrutide side effects starts with proper dosing. Trials use a slow escalation: starting at 2 mg weekly, increasing every 4 weeks to a maintenance dose of up to 12 mg. This gradual increase significantly reduces nausea and vomiting. Taking the injection with a small meal can help. Anti-nausea medications like ondansetron may be prescribed for severe cases.
Hydration is critical. Diarrhea and vomiting can cause dehydration, which worsens fatigue and headache. Electrolyte replacement drinks or oral rehydration solutions help. For constipation, increased water intake and fiber supplements (psyllium) are often effective. Most retatrutide side effects diminish after 4-8 weeks as the body adjusts.
If you experience severe abdominal pain, persistent vomiting lasting more than 24 hours, signs of gallbladder issues (pain in upper right abdomen, fever), or allergic reactions (difficulty breathing, facial swelling), seek immediate medical attention. Do not simply stop the drug without clinical guidance, but do not ignore serious symptoms.
Because retatrutide is still investigational, long-term retatrutide side effects are unknown. Phase 3 trials are designed to track participants for one to two years. But post-approval safety data (if approval happens) would take years to accumulate. Unknown risks include potential effects on the pancreas (chronic inflammation), thyroid (long-term C-cell stimulation), and cardiovascular system (heart rhythm). The glucagon pathway's long-term metabolic effects are not fully understood.
According to the NIH, all GLP-1 class drugs carry a boxed warning for thyroid C-cell tumors based on rodent studies. While human data has not shown the same risk, monitoring is required. Retatrutide side effect profiles will become clearer as Phase 3 data is published. For now, any use must be under direct clinician supervision with regular follow-up. Read our clinician-led options page for more on supervision requirements.
Early data suggests retatrutide may cause slightly higher rates of nausea during dose escalation due to triple receptor activation. However, side effects are similar in type and severity for most users. Individual tolerance varies significantly.
No. Retatrutide side effects are reversible when the drug is stopped. Gastrointestinal effects resolve within days to weeks after discontinuation. No permanent side effects have been documented in trials to date.
Older adults may be more sensitive to gastrointestinal side effects and dehydration. Trials include older participants, but individual risk assessment by a clinician is essential. Kidney function and medication interactions must be reviewed.
The official Eli Lilly clinical trial registry pages list known side effects from completed phases. Because retatrutide is not approved, there is no FDA package insert. The most reliable source is the clinicaltrials.gov database.
Yes. Many trial participants use prescription anti-nausea medications like ondansetron or over-the-counter options like meclizine. Always discuss with your clinician before adding any medication to avoid interactions.
Both cause gastrointestinal side effects. Retatrutide adds glucagon agonism, which may increase nausea frequency slightly. No head-to-head trials have been published. Individual response varies.
Retatrutide side effects: Most common are nausea (40-50%), diarrhea (30-40%), vomiting (20-30%), constipation (15-25%). Less common: increased heart rate, fatigue, injection site reactions. Serious risks: possible thyroid C-cell tumors (animal studies), pancreatitis, gallbladder disease. Contraindicated for medullary thyroid cancer history or MEN2. Most side effects are dose-dependent and decrease after 4-8 weeks. Retatrutide is investigational; full safety profile not complete. Always use under clinician supervision. This site provides an affiliate referral to telehealth intake for medical consultation.